Vandria is delighted to announce the second closing of its Series A financing, bringing the final amount raised to date to $30.7M (CHF 28.3M). Vandria welcomes new institutional investors Hevolution Foundation and Dolby Family Ventures, who have joined its founding venture investor, ND Capital.
Hevolution focuses on investing in innovative science to support healthy aging, while Dolby Family Ventures, in life sciences, invests in early-stage precision neuroscience and platform companies. Vandria is a great fit for their portfolios, as the company is developing first-in-class small molecule mitophagy inducers against a novel target to rejuvenate cells and treat age-related and chronic diseases.
Since the first Series A close in December at $20.6M (CHF 18M), Vandria has made rapid progress:
- Developed its platform and portfolio
- Advanced its lead program, VNA-318, a patent-protected, brain-penetrant, first-in-class mitophagy inducer. VNA-318 is on track to enter clinical trials in Europe in the coming weeks
- Expanded its team and moved to dedicated lab facilities at Superlab Suisse on the Biopôle Lausanne campus
- Secured CHF 4.2M in prestigious non-dilutive funding: two Innosuisse grants to support VNA-318 and a Eurostars grant to support the generation of preclinical data for mitophagy drug candidates in Vandria’s muscle program
Vandria’s CEO, Klaus Dugi, said: “This financing supports our transformation into a clinical-stage company as we progress further in clinical development, with the Series A funding providing runway to complete the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) first-in-man Phase 1 study of VNA-318 and to initiate three parallel Phase 1b / 2a efficacy studies in 2025, subject to positive progress in Phase 1 and regulatory approvals.
